About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01149083

Veliparib With or Without Carboplatin in Treating Patients With Stage III or Stage IV Breast Cancer

Study identifier: NCT01149083
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

  • Histologically confirmed metastatic or locally advanced breast cancer
    • Disease not amenable to surgery
    • Standard curative measures do not exist or are no longer effective
  • Patient must have a known BRCA mutation
  • Measurable disease by RECIST criteria

Type of study:

Phase II randomized study

Treatment:

  • Arm I: Patients receive oral veliparib twice daily on days 1-21.
  • Arm II: Patients receive carboplatin IV over 30 minutes on day 1 and veliparib as in
    arm I.

Study sites:

Arizona
Scottsdale
Mayo Clinic Scottsdale   
Contact: Donald W. Northfelt 480-301-4411 Northfelt.Donald@mayo.edu     

California
Duarte
City of Hope Comprehensive Cancer Center
Contact: George Somlo 626-256-4673 GSomlo@coh.org

Los Angeles
USC/Norris Comprehensive Cancer Center and Hospital
Contact: Agustin A. Garcia 323-865-3900 garcia_a@ccnt.usc.edu     

Davis
University of California Davis Cancer Center
Contact: David R. Gandara 916-734-3771 david.gandara@ucdmc.ucdavis.edu

Colorado   
Denver
University of Colorado Cancer Center at UC Health Sciences Center
Contact: Virginia F. Borges 303-724-0186 virginia.borges@ucdenver.edu

Florida
Jacksonville
Mayo Clinic - Jacksonville
Contact: Edith A. Perez 904-953-7283 perez.edith@mayo.edu        

Illinois
Chicago
University of Chicago Cancer Research Center     
Contact: Contact: Rita Nanda 773-834-2756 rnanda@medicine.bsd.uchicago.edu

Maryland
Baltimore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins     
Contact: Clinical Trials Office - Sidney Kimmel Cancer Ce    410-955-8804     jhcccro@jhmi.edu   

Massachusetts
Boston
Beth Israel Deaconess Medical Center     
Contact: Nadine M. Tung 617-667-7082 ntung@caregroup.harvard.edu      

Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute          
Contact: Judy Garber, MD     617-632-2282     judy_garber@dfci.harvard.edu   

Massachusetts General Hospital 
Contact: Steven J. Isakoff 617-726-4920 sisakoff@partners.org        

Minnesota
Rochester
Mayo Clinic Cancer Center           
Contact: Matthew P. Goetz 507-284-2511 goetz.matthew@mayo.edu        

Missouri
Saint Louis
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis       
Contact: Cynthia X. Ma, MD, PhD     314-362-9383      

New York
New York     
New York Weill Cornell Cancer Center at Cornell University
Contact: Tessa Cigler 212-821-0736 tec9002@med.cornell.edu        

Memorial Sloan-Kettering Cancer Center
New York, New York, 10065
Contact: David Paul Kelsen, MD     212-639-2428       

Pennsylvania
Hershey
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
Contact: Chandra P. Belani 717-531-1078 cbelani@psu.edu    

Pittsburgh
Magee Womens Hospital
Contact: Shannon L. Puhalla 412-641-5792 puhallasl@upmc.edu        

UPMC Cancer Centers    
Pittsburgh, Pennsylvania, 15232
Contact: Shannon L. Puhalla 412-641-5792 puhallasl@upmc.edu        

Texas
Houston
M. D. Anderson Cancer Center at University of Texas
Contact: Banu K. Arun barun@mdanderson.org

Canada
Ontario
University Health Network-Princess Margaret Hospital Recruiting
Contact: Srikala S. Sridhar 416-946-2249

Page updated 06/20/13


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org